Filana Therapeutics, Inc. FLNA
0.47 USD +0.04 (+10.56%)
Regular-session close
0.48 +0.01 +2.13%
After hours · Nov 16, 7:22 PM ET
0.39 Day range 0.4839
0.39 52-week range 3.45
- YTD
- -76.26%
- 1 year
- -82.97%
News
globenewswire.com Filana Therapeutics Names Biopharma Executive Jill M. Quigley to Board AUSTIN, Texas, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Filana Therapeutics, Inc. (NASDAQ: FLNA), a biotechnology company focused on developing therapies for Tuberous Sclerosis Complex (TSC)-related…
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Sonoma Pharmaceuticals (NASDAQ:SNOA) stock increased by 13.2% to $1.29 during Wednesday's pre-market session. The company's market cap stands at $5.4 million. The company's, Q2 earnings came…benzinga.com Filana Therapeutics Q3 EPS $(0.22) Beats $(0.24) Estimate Filana Therapeutics (NASDAQ:FLNA) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.24) by 8.33 percent. This is unchanged from the same period last year.
benzinga.com Filana Therapeutics Announces A Study Published By Yale Researchers Of New Preclinical Research On Simufilam Examined Simufilam's Impacts In Human Cell Line To Eliminate Tuberous Sclerosis Complex 2 Gene To Model Cellular Changes Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing simufilam for the treatment of Tuberous Sclerosis Complex
